NYESO-1/LAGE-1s and prame are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Pollack, Seth M ^a,b   Li, Yonqing ^a   Blaisdell, Megan J ^a   Farrar, Erik A ^a   Chou, Jeffrey ^a,b   Hoch, Benjamin L ^b   Loggers, Elizabeth T ^a,b,c   Rodler, Eve ^b   Eary, Janet F ^d   Conrad, Ernest U ^b   Jones, Robin L ^a,b   Yee, Cassian ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; EPITOPE; LAGE 1L ANTIGEN; LAGE 1S ANTIGEN; NY ESO 1 ANTIGEN; PRAME ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; CTAG1B PROTEIN, HUMAN; CTAG2 PROTEIN, HUMAN; HLA ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PEPTIDE; PRAME PROTEIN, HUMAN; PRIMER DNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL THERAPY; CHONDROSARCOMA; CONTROLLED STUDY; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROTEIN INDUCTION; PROTEIN TARGETING; REFERENCE VALUE; T LYMPHOCYTE; TARGET CELL; BIOSYNTHESIS; CHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; METABOLISM; METHODOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TESTIS;

ANTIGENS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; CHONDROSARCOMA; DNA PRIMERS; EPITOPES; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MEMBRANE PROTEINS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; TESTIS;

EID: 84863287359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032165     Document Type: Article

References (40)

1. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, et al. (2003) From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 23: 1245-1278.
2. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, et al. (2008) The clinical approach towards chondrosarcoma. Oncologist 13: 320-329.
3. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, et al. (2000) Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br 82: 55-61.
4. Staals EL, Bacchini P, Bertoni F, (2006) Dedifferentiated central chondrosarcoma. Cancer 106: 2682-2691.
5. Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, et al. (2004) Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 86-A: 2412-2418.
6. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
7. Rosenberg SA, Spiess P, Lafreniere R, (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
8. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
9. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ, (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
10. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, et al. (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 97: 12198-12203.
11. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, et al. (2011) Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol.
12. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL, (2011) Immune-based therapies for sarcoma. Sarcoma 2011: 438940.
13. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, et al. (2008) Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112: 1876-1885.
14. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, et al. (2001) Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71: 295-301; discussion 301-292.
15. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, et al. (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116: 1908-1918.
16. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, et al. (2001) Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24: 151-161.
17. Oi S, Natsume A, Ito M, Kondo Y, Shimato S, et al. (2009) Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol 92: 15-22.
18. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, et al. (2010) The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 34: 899-905.
19. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, et al. (2011) Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine. Cancer Immunol Immunother 60: 1243-1255.
20. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, et al. (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12: 5777-5785.
21. Block JA, Inerot SE, Gitelis S, Kimura JH, (1991) The effects of long term monolayer culture on the proteoglycan phenotype of a clonal population of mature human malignant chondrocytes. Connect Tissue Res 26: 295-313.
22. Block JA, Inerot SE, Gitelis S, Kimura JH, (1991) Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 73: 647-658.
23. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N, (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196: 121-135.
24. Li Y, Yee C, (2008) IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111: 229-235.
25. Riddell SR, Greenberg PD, (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128: 189-201.
26. Cui W, Taub DD, Gardner K, (2007) qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res 35: D805-809.
27. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, et al. (2010) Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol 184: 4284-4294.
28. Chou Jeffrey, Voong Lilien, Mortales ChristieL, Towlerton AndreaHM, Pollack SethM, et al. (in press) Epigenetic modulation to enable antigen-specific T cell therapy of colorectal cancer. Journal of Immunotherapy.
29. Figueiredo DL, Mamede RC, Spagnoli GC, Silva WA Jr, Zago M, et al. (2011) High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 33: 702-707.
30. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, et al. (2009) High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 125: 1365-1371.
31. Schwab JH, Boland PJ, Agaram NP, Socci ND, Guo T, et al. (2009) Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 58: 339-349.
32. Hiraki A, Ikeda K, Yoshino T, Kaneshige T, Kiura K, et al. (2001) Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. Biochem Biophys Res Commun 286: 786-791.
33. Bluman EM, Coulie PG, Xiaojuan S, Machan J, Lin C, et al. (2007) Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules. J Orthop Res 25: 678-684.
34. Lin C, Mak S, Meitner PA, Wolf JM, Bluman EM, et al. (2002) Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene 285: 269-278.
35. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, et al. (2007) Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 31: 1521-1528.
36. Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP, (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46: 796-804.
37. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803.
38. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, et al. (2006) De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66: 1105-1113.
39. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, et al. (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10: 8396-8404.
40. Pattyn F, Speleman F, De Paepe A, Vandesompele J, (2003) RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 31: 122-123.